News News Details

The successful submission of the first share of the new crown oral drug is welcomed by The Hong Kong

Date: 2022-08-05
Views: 5646

Just recently, the Hong Kong Stock Exchange welcomed the successful submission of the first share of the new crown oral drug.

 

The successful submission of the first share of the new crown oral drug is welcomed by The Hong Kong


On August 4, the Hong Kong Stock Exchange disclosed that Henan Zhenzhen Biotechnology Co., Ltd. (hereinafter referred to as 'Genuine Biotech') submitted a listing application to the Hong Kong Stock Exchange.

 

Efung Capital is the only investment institution to accompany the growth of Genuine Biotech, and it has led two consecutive rounds of investment for the company. The first was in November 2020, when it exclusively led the series A financing of Genuine Biotech; the second occurred in August 2021, when it led the investment in Genuine Biotech’s USD 100 million Series B financing.

 

Genuine Biotech was established in 2012. Having 10 years of development behind it, the company has entire industry chain ability for innovative drug discovery, clinical research and development, manufacturing and commercialisation, and has a firm commitment to become a world-competitive biopharmaceutical company.

 

At the present time, Genuine Biotech has made noteworthy progress in the field of anti-virus. On July 25, 2022, the State Drug Administration proclaimed that, in accordance with the relevant provisions of the Drug Administration Law and specific drug approval procedures, the State Drug Administration conducted emergency review and approved Henan Zhenzhen Biotechnology Co., Ltd. with certain conditions. The registration application for Azvudine tablets to treat the novel coronavirus pneumonia has been approved. This is China's first oral anti-COVID-19 drug with entirely autonomous intellectual property rights.


On the morning of August 2, Genuine Biotech held the 'New Crown Oral Drug Azvudine Tablet Production Ceremony' in Pingdingshan, symbolising that Azvudine Tablet officially came into the production stage. This will supply robust support for our country to scientifically protect people’s health by preventing and controlling the epidemic. China's strength has contributed to the world's early victory over the new crown pneumonia epidemic.

 


Related News / Recommended news More
2022 - 08 - 10
On August 9, the National Health Commission issued a notice, according to the approval opinions of the State Food and Drug Administration on the application for registration of additional indications for the treatment of novel coronavirus pneumonia with azvudine tablets. In order to further improve the antiviral treatment scheme for novel coronavirus pneumonia, the drug was included in the diagnos...
2022 - 08 - 05
Just recently, the Hong Kong Stock Exchange welcomed the successful submission of the first share of the new crown oral drug. On August 4, the Hong Kong Stock Exchange disclosed that Henan Zhenzhen Biotechnology Co., Ltd. (hereinafter referred to as 'Genuine Biotech') submitted a listing application to the Hong Kong Stock Exchange. Efung Capital is the only investment institution...
2022 - 08 - 01
Recently, Apexigen, a portfolio company of Efung Capital, and Brookline Capital Acquisition Corp.-a Special Purpose Acquisition Company (SPAC)-entered an official merger process, resulting that Brookline Capital Acquisition Corp. was renamed to Apexigen, Inc. Guided and led by Dr. Xiaodong Yang, president as well as Chief Executive Officer (CEO) of Apexigen company, the firm joined the listing of ...
2022 - 07 - 25
On July 25, 2022, the State Drug Administration proclaimed that, in accordance with the relevant provisions of the Drug Administration Law and specific drug approval procedures, the State Drug Administration conducted emergency review and approved Henan Zhenzhen Biotechnology Co., Ltd. with certain conditions. The registration application for Azvudine tablets to treat the novel coronavirus pneumon...
Address: 505 China Resources Building, 2666 Keyuan South Road, Nanshan District, Shenzhen
TEL:0755-8831-6141
E-mail:info@efungcapital.com
Copyright ©2018 - 2021 Shenzhen Efung Investment Management Co. Ltd.
Rhino Cloud provides enterprise cloud services
犀牛云提供云计算服务